glp 1 for metabolic syndrome Why are GLP-1 agonists being used to treat patients with nonalcoholic fatty liver disease? glp 1 for metabolic syndrome

One of the five peptides was removed from Category 2 in September 2024 and is currently undergoing PCAC review

Starting weight loss therapy with uncontrolled hypothyroidism may: Confound assessment of treatment efficacy Complicate symptom attribution (fatigue, constipation overlap) Necessitate multiple medication adjustments simultaneously Practically speaking, patients may benefit from demonstrating stable thyroid function on consistent levothyroxine dosing before adding weight loss medications, though this is not a strict requirement

& Calabro, P

Only three glycosylation sites were found across the 93 PsomGSTs

Wu AB, Feng J, Yu, et al

Molecular recognition of an acyl-peptide hormone and activation of ghrelin receptor